Received Oct 31, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RSV | RSV (AREXVY) | GLAXOSMITHKLINE BIOLOGICALS | UNK | b7d73 | — |
36 weeks pregnant given Arexvy; Wrong vaccine administered; a patient who was 36 weeks pregnant was given Arexvy instead of Abrysvo; This non-serious prospective pregnancy case was reported by a nurse via call center representative and described the occurrence of vaccine exposure during pregnancy in a 26-year-old female patient who received RSVPreF3 adjuvanted (Arexvy) (batch number b7d73, expiry date 05-DEC-2026) for prophylaxis. Co-suspect products included RSV vaccine prot. subunit PreF 2v (Abrysvo) for prophylaxis. On 09-OCT-2025, the patient received Arexvy. On an unknown date, the patient received Abrysvo. On 09-OCT-2025, an unknown time after receiving Arexvy and not applicable after receiving Abrysvo, the patient experienced wrong vaccine administered (Verbatim: Wrong vaccine administered) and product use in unapproved population (Verbatim: a patient who was 36 weeks pregnant was given Arexvy instead of Abrysvo). On an unknown date, the patient experienced vaccine exposure during pregnancy (Verbatim: 36 weeks pregnant given Arexvy). The outcome of the vaccine exposure during pregnancy, wrong vaccine administered and product use in unapproved population were not applicable. Pregnancy exposure: Pregnancy Exposure (Arexvy): To mother in third trimester Pregnancy Exposure (Abrysvo): To mother in third trimester Pregnancy Outcome: Pregnancy was ongoing Additional Information: GSK Receipt Date: 09-OCT-2025 Registered nurse who stated that a patient who was 36 weeks pregnant was given Arexvy instead of Abrysvo.